Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 203.50 200.00 207.00 203.50 203.50 203.50 282,630 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 365

Amryt Pharma Share Discussion Threads

Showing 4976 to 4996 of 6575 messages
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
DateSubjectAuthorDiscuss
13/9/2019
09:06
If you buy AMYT shares before 20th Sept and keep them until after 20th Sept you will be on the register to receive the CVRs. Its much the same as a holding a share that goes ex-dividend on a certain day. You can buy this share the day before the XD date and sell it the day after and still receive the dividend. But its not necessarily free money because the market should assume that the current AMYT share price already includes the value of the CVR's. After 20th September this element is removed from the AMYT share, so the AMYT share price should fall in value. But this fall in value should be compensated by the fact that you would hold this value through your separate ownership of the CVR. My view is that the market probably doesn't know what value to apply to the CVR as its potential payout is subject to so many outcomes. I think the AMYT share price will fall only around 5p - 10p to reflect the ex CVR status and then quickly recover.
dlm2602
13/9/2019
08:05
Buys showing as sells
alphabravo321
13/9/2019
07:33
papillon what's happening on 24 sept?
ali47fish
12/9/2019
22:12
I see Bronxville has changed his tune!! LOL. He's definitely changed his mind on the debt that AMYT + Aegerion will have. Bronxville Posted in: AMYT Posts: 1,186 Price: 12.375 No Opinion RE: info please 22 May 2019 14:02 It could be American hedge funds dumping their worthless Aegerion bonds onto Amryt. You would hope Amryt management are smarter than that. Bronxville Posts: 1,185 Price: 106.00 No Opinion RE: The Prospects Tue 12:23 If it gets Nasdaq listing could be good.. Don't mind having debt on the books with 2 marketable drugs as financing is so cheap at the moment.. Bronxville Posts: 1,185 Price: 115.00 No Opinion Sept 24th Today 16:16 I wonder could this shoot ALOT higher than 1.48 prior Sept 24th. Shares are very tightly held so a technical bounce could be on the cards.
papillon
12/9/2019
21:49
Good point, waterloo. I made the same point back in May after the Aegerion deal was announced. papillon 30 May '19 - 09:29 - 4509 of 4849 "Also Socioderm were promised extra money (US$100m, or 50% of sale price whichever was the lesser) if a PRV was issued by the FDA and subsequently sold. AMYT shareholders will be getting NOTHING in return for a PRV being sold."
papillon
12/9/2019
18:58
the more i think about it in the absence of an ex date buying the shares now for the CVRs is taking a punt on getting on the register by 8pm on sept 20th, which is fairly unlikely so i reckon probably too late
richman777114
12/9/2019
18:48
Annoying thing about it though is IF Ap101 does get approval, it comes with a fast track. One recently sold for $95m (in years gone by have reached $300m in value). Still I guess the combined business gets the benefit, but would have been better to have had a % of that as part of the CVR.
waterloo01
12/9/2019
18:27
record date for the CVRs is 20th sept ie date one needs to be on register but no ex date given for dealing with, then without, the entitlement to the CVRsex date always some days prior to record date to allow for registrationsurely one cannot buy up to 20th and also be on the register as at the 20th?confusing
richman777114
12/9/2019
17:01
The value of the CVRs is made crystal clear in the RNS of the 27th, no need for any complex calculations: The value of these CVRs is up to US$1.48 per Ordinary Share (GBP1.22 based upon an exchange rate of GBP1:$1.21). The CVRs are payable in three tranches, being: -- A contingent entitlement of up to a maximum amount of $35,000,000 subject to the Food & Drug Administration ("FDA") issuing a Qualifying Approval in respect of AP101 prior to 1 July 2022; i.e. up to about 50p per share -- A contingent entitlement of up to a maximum amount of $15,000,000 subject to the European Medicines Agency ("EMA") issuing a Qualifying Approval in respect of AP101 prior to 1 July 2022; i.e. up to about 22p per share and -- A contingent entitlement of up to a maximum amount of $35,000,000 on Amryt achieving a 12-Month Trailing Net Product Revenue in excess of $75,000,000 from sales of AP101 prior to 30 June 2024. i.e. up to about 50p per share If none of the milestones are achieved, Scheme Shareholders and Option holders will not receive any additional consideration under the terms of the CVRs. In these circumstances, the value of each CVR would be zero. i.e. 0p per share Text in bold is mine.
webpax
12/9/2019
15:04
"Are we to expect a bit of a sell off after 20th Sept?" Your guess is as good as mine, richpassi. I did think there would be a sell off after 20th September, richpassi, if investors were buying just to obtain the CVR's, but after the rise yesterday following the release of the RNS @ 3pm announcing the "Acquisition of Aegerion" and also after reading Mark Taub's article I'm now convinced that investors are buying because of the RTO involving Aegerion, the 148p placing price and the proposed Nasdaq listing where AMYT will likely initially trade at a substantial discount to it's peer group. Hence my best guess, richpassi, is that there will NOT be a sell off after 20th September. ATB, buddy.
papillon
12/9/2019
15:03
postivityNocolas, It's a bit rich being petty about someone else being petty. The size of the investment is also not that relevant. It's all relative. Looking forward to seeing where this settles once the dust clears. I'm certainly hoping for something North of £1.50, possibly higher as people buy for the CVR before the deadline.
waterloo01
12/9/2019
14:58
£2,000 - a lot of money to some folk! Don’t knock it!
bazworth
12/9/2019
14:34
And the best thing of all he has about £2000 worth of shares in Amryt !!!!
positivitynicholas
12/9/2019
14:32
Oh don’t worry Pappy has got all the time in the world to spare regurgitating information that is freely available to anyone who wants to read it but of course he makes it sound like he has created the news through undercover painstaking covert research 😂 what a 😂
positivitynicholas
12/9/2019
14:21
Thanks for that Pap very to the point. Glad that you got the time to spare as I'm beavering away in the workshop ;) Are we to expect a bit of a sell off after 20th Sept ? Ive been in long enough now :( but not going anywhere yet a while :)
richpassi
12/9/2019
12:27
I saw this link posted on the lse AMYT bb, richpassi. It shows that new AMYT could be very undervalued even at £1.48 per share compared to it's Nasdaq peer group, when it lists on Nasdaq. According to this article AMYT could be a very good performer in 2020. Nasdaq quoted NVLN, which will end up with 8.1% of the new AMYT shares, is seriously undervalued according to the author. NVLN seems like an excellent short term punt for those who trade shares on Nasdaq. hTTps://seekingalpha.com/article/4290742-novelions-8_1-percent-stake-amryt-worth-1_50-share?dr=1 Note about the author of the article, Mark Taub: "Mark Taub is an experienced bankruptcy lawyer and distressed investor who has represented debtors, creditors and investors in distressed companies as an attorney and has invested across the capital structure of distressed companies as a portfolio manager. For the last 10 years Mr. Taub has managed a general distressed portfolio for Mohawk Capital and other institutional investors consisting of defaulted securities, high yield bonds, leveraged loans and post-reorg equities as well as managing a portfolio of trade credit insurance and reinsurance policies. Additionally, Mr. Taub co-founded and co-managed a distressed energy investment business. Mr. Taub has invested both passively and actively, including sitting on official and ad hoc committees, generating enhanced returns through the use of the bankruptcy legal process including investments in Visteon and Alpha Natural Resources among others. Mr. Taub's unique background as a bankruptcy attorney and distressed investor has given him the perspective to both work out existing positions to maximize their value as well as identify pockets of value across all parts of the capital structure".
papillon
12/9/2019
12:08
Well richpassi, this is what the RNS dated 27/8/2019 states: "Following the admission of the Interim Placing Shares to trading on AIM and Euronext Growth, but before the Transaction to acquire Aegerion completes, Amryt will have 53,149,070 Ordinary Shares in issue. This figure of 53,149,070 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules." "Contingent Value Rights ("CVRs") Shareholders in Amryt, on the CVR Record Date, will (conditional on closing of the Transaction occurring) receive CVRs pursuant to which up to $85 million may become payable to Amryt's existing Shareholders and Option holders if certain approval and revenue milestones are met in relation to one of Amryt's principal products, AP101. The CVR Record Date is 20 September 2019. If Shareholders sell their Ordinary Shares in advance of the CVR Record Date they will not be entitled to receive CVRs. The value of these CVRs is up to US$1.48 per Ordinary Share (GBP1.22 based upon an exchange rate of GBP1:$1.21). The CVRs are payable in three tranches, being: -- A contingent entitlement of up to a maximum amount of $35,000,000 subject to the Food & Drug Administration ("FDA") issuing a Qualifying Approval in respect of AP101 prior to 1 July 2022; -- A contingent entitlement of up to a maximum amount of $15,000,000 subject to the European Medicines Agency ("EMA") issuing a Qualifying Approval in respect of AP101 prior to 1 July 2022; and -- A contingent entitlement of up to a maximum amount of $35,000,000 on Amryt achieving a 12-Month Trailing Net Product Revenue in excess of $75,000,000 from sales of AP101 prior to 30 June 2024. If any such milestone is achieved, New Amryt may elect to pay the CVR Holders by the issue of New Amryt Shares or Loan Notes. If New Amryt elects to issue Loan Notes to CVR Holders, it will settle such loan notes in cash 120 days after their issue. If none of the milestones are achieved, Scheme Shareholders and Option holders will not receive any additional consideration under the terms of the CVRs. In these circumstances, the value of each CVR would be zero. The terms of the CVRs will be governed by the CVR Instrument, further details of which are set out in the Admission Document." >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> So the VERY BEST CASE scenario (which may never be reached) if AP101 passes all the "milestones" is US$85m divided by 53,149,070 shares. That comes out as a MAXIMUM of £1.60p per AMYT share BEFORE the Aegerion acquisition/RTO takes place. So, richpassi, if AMYT passes all the hurdles (milestones) placed in it's way you could end up with a MAXIMUM of £1.60 per old AMYT share, either in cash, shares in new AMYT, or a combination of both, sometime in the future. That equates to 26.67p per AMYT share BEFORE the 1 for 6 consolidation. I'm not attaching any value to the CVR's until I see what the Phase III result is for AP101 when it's released early next year. However I believe the CVR's are worth having, even if I'm ascribing no value to them at present, which is why I've topped up recently. I think the CVR's are a gamble worth having in the hope that AP101 passes some of the milestones set for it. Fingers crossed! Fingers crossed it passes all the milestones!! LOL.
papillon
12/9/2019
08:49
I understand your thoughts are better for Amyt than Logp and of course heaven forbid amyt was in the same state !!! I was only commenting on the bb not the companies. You are doing well not to retaliate on this board , it only feeds them :( and yes it is your upbringing that shows through at times lol On the fundamental side I'm glad you have mentioned the advfn MKT capital of amyt as I was trying to value best possible outcome of CVR and was obviously using duff figures ! How many shares do we have in issue now ? And what could the possible CVR value be per share, in your opinion
richpassi
11/9/2019
21:45
Post today on the lse bb: Candid Posts: 223 Price: 115.00 No Opinion RE: Chapter 11 approved Today 20:10 I don’t think the current share price (115p) is reflecting the deal yet, the gap will probably close, it’s just one of those things. The enlarged company will have 176,349,543 shares following issue of the consideration for the deal including the equity raise. The equity raise involves just 33,453,666 shares. If any funds or institutions want to get hold of a sizeable stake then they will be paying £1.48 per share. The raise is also ‘backstopped’ by Aegerion bondholders, in other words Athyrium, Highbridge, UBS and Whitebox, have agreed to purchase any unsubscribed portion of the equity raise.
papillon
11/9/2019
17:58
No its not pointless Bazworth its good to see I wasn't the only one thinking the same :( Sad to this turn into the Logp bb !
richpassi
11/9/2019
17:43
It never ceases to surprise me how rude folk can be on these bulletin boards. Completely pointless, as I guess this post is too!!
bazworth
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:34:27